Jump Directly to Webcast
Diagnoses of attention-deficit/hyperactivity disorder (ADHD) in adults have risen in recent years, as have national conversations about the often-misunderstood neurological disorder. What’s driving this elevated focus? And what are the implications for public education, access to care, treatment strategies, and related government policies?
The National Academies of Sciences, Engineering, and Medicine’s Health and Medicine Division has convened a panel of subject matter experts to explain the brain science behind ADHD, explore the patient experience, discuss current and future treatment landscapes, and more in a free public webinar. This informal conversation will be valuable to individuals diagnosed with ADHD and their families, health care professionals, students, journalists, and anyone who would simply like to learn more about the topic. An audience Q&A will follow the discussion.
Panelists:
Amy F.T. Arnsten, Ph.D., is the Albert E. Kent Professor of Neuroscience at the Yale University School of Medicine. She is an international expert on the molecular regulation of the primate prefrontal cortex, the brain region most often afflicted in ADHD, including how this brain area is altered by uncontrollable stress, aging and inflammation. Arnsten developed a nonstimulant treatment for ADHD, guanfacine (Intuniv), that was FDA-approved for this indication in 2009. This is one of the few examples where knowledge arising from basic science has successfully translated to a treatment for human cognitive disorders. Guanfacine is also being used off-label to treat other prefrontal cortical disorders, including PTSD and cognitive deficits from long-COVID. Arnsten is a member of the National Academy of Medicine and the recipient of the Goldman-Rakic Prize for Outstanding Research in Cognitive Neuroscience. She received her B.A. in Neuroscience from Brown University in 1976, creating the Neuroscience major, and her Ph.D. in Neuroscience from University of California, San Diego in 1982.
David W. Goodman, M.D., is Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Clinical Associate Professor of Psychiatry and Behavioral Sciences at the Norton School of Medicine, State University of New York-Upstate. An internationally recognized expert, he has presented over 750 lectures to medical specialists, authored peer-reviewed scientific papers, conducted clinical research on several of the ADHD medications now on the market, serves as a consultant to the NFL, widely quoted in national media, teaches 4th-year psychiatric residents at the Johns Hopkins School of Medicine and State University of New York-Upstate, served on the executive board of APSARD (American Professional Society for ADHD and Related Disorders), and as a member of the APSARD Task Force for the development of the APSARD’s U.S. Clinical Practice Guidelines for the Diagnosis and Treatment of ADHD in adults.
Tamara Rosier, Ph.D., is the founder of the ADHD Center of West Michigan, where she and her staff of coaches and therapists work with individuals with ADHD (and their families) to learn strategies and develop new skills to live effectively with ADHD. Rosier's experiences as a college administrator, a professor, and a high school teacher afforded her valuable insight into ADHD and how it affects one's life. She is also the past president of the ADHD Coaches Organization and co-chair of the International Conference on ADHD. She has published numerous articles about living with ADHD and frequently speaks at conferences. Her books, Your Brain's Not Broken, and You, Me and Our ADHD Family, provide strategies for managing the emotional aspects of ADHD.
Relevant Resources:
Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop Interactive Web Page